SCHEMBL6645443

SCHEMBL6645443

Cc1cccc2cc(Cl)[nH]c(=O)c12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.56
▸ PARP1 P09874 6/20 0.50
▸ DAO P14920 2/20 0.45
▸ DDO Q99489 1/20 0.45
▸ BRD4 O60885 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ HSP90AB1 P08238 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ SAE1 Q9UBE0 1/20 0.40
▸ UBA2 Q9UBT2 1/20 0.40
▸ TYMS P04818 3/20 0.39
▸ PBRM1 Q86U86 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6646755 0.83 PARP1 (0.49) CYP1A2PARP1DAOMEN1KMT2A
SCHEMBL6648718 0.76 MEN1 (0.49) PARP1KDM4EGAAMEN1ALDH1A1
SCHEMBL6644354 0.76 TNKS (0.49) CYP1A2PARP1DAODDOKDM4E
SCHEMBL9262831 0.73 TYMS (0.41) CYP1A2PARP1DAODDOKDM4E
SCHEMBL12943462 0.73 CYP1A2 (0.46) CYP1A2PARP1DAODDOBRD4
SCHEMBL26287906 0.72 CYP1A2 (1.00) CYP1A2PARP1DAODDOBRD4
SCHEMBL6649111 0.72 PDGFRB (0.47) CYP1A2PARP1KDM4EALDH1A1TNKS
SCHEMBL20422072 0.71 PARP1 (0.70) CYP1A2PARP1TYMSPBRM1TNKS
SCHEMBL29784203 0.71 KDM4E (0.60) PARP1KDM4EGAAMEN1ALDH1A1
SCHEMBL150458 0.71 KDM4E (0.60) PARP1KDM4EGAAMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-09-09 — — US disclosed
EP-1396488-A1 FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-03-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof PARP11, PARP1, CD38 CYP1A2 1129/4885PARP1 2/4885DAO 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback